Accelerated medical clearance and surgery
OtherRapid medical clearance with targeted arrival to the operating room within 6 hours of eligibility criteria criteria met.
NCT Number: NCT04743765
The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The trial will also assess secondary outcomes at 90 days after randomization: inability to independently walk 3 metres, time to first mobilization (first standing and first full weight bear), composite and individual assessment of major complications (e.g., mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke), delirium, length of stay, pain, and quality of life.
Interested in participating?
Request Info45 year and older
All sexes
Interventional
Not applicable
The John Hunter Hospital, New Lambton Heights, New South Wales, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Rapid medical clearance with targeted arrival to the operating room within 6 hours of eligibility criteria criteria met.
Time frame: Within 90 days post randomization
Death due to all causes
Time frame: Within 90 days post randomization
Ability to independently walk 3 meters (10 feet) or across a room without human assistance. Patients who require a cane or walker, but not human assistance, will be classified as able to walk independently. Patients who require assistance to get out of a chair, but can walk independently once they get up, will be classified as able to walk independently.
Time frame: Within 90 days post randomization
Composite includes vascular and nonvascular mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke.
Time frame: Within 90 days post randomization
Any death with a vascular cause and includes those deaths following a myocardial infarction, sudden cardiac arrest, stroke, cardiac revascularization procedure (i.e., percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery), heart failure, pulmonary embolus, cardiovascular hemorrhage, or deaths due to an unknown cause
Time frame: Within 90 days post randomization
Any death due to a clearly documented non-vascular cause.
Time frame: Within 90 days post randomization
Diagnosis of MI according to 4th universal definition of myocardial infarction
Time frame: Within 90 days post randomization
at least one clinical sign(s) or symptom(s) (e.g elevated jugular venous pressure, respiratory rales/crackles, crepitations, hypoxia, tachypnea or presence of S3) with at least one of the following:
Time frame: Within 90 days post randomization
Either - 1. a new focal neurological deficit thought to be vascular in origin with signs or symptoms lasting more than 24 hours or leading to death; or 2. a new focal neurological deficit thought to be vascular in origin with signs or symptoms lasting less 24 hours with a positive neuroimaging consistent with a stroke
Time frame: Within 90 days post randomization
Length of hospital stay from randomization to hospital discharge
Time frame: Within 7 days and 90 days post randomization
Time frame: Within 7 days and 90 days post randomization
Moderate to severe pain is defined as any pain score ≥3 on 10 points scale.
Time frame: Within 90 days post randomization
Documentation of atrial fibrillation or atrial flutter of any duration on an ECG, telemetry tracing, or rhythm strip and results in angina, congestive heart failure, symptomatic hypotension, or is followed by initiation or a dose increase of a rate controlling drug, antiarrhythmic drug, or electrical cardioversion.
Time frame: Within 90 days post randomization
Revascularization procedures including coronary artery bypass graft or percutaneous coronary intervention surgery.
Time frame: Within 90 days post randomization
Venous pulmonary embolism or deep venous thrombosis
Time frame: Within 90 days post randomization
The diagnosis of PE requires any one of the following:
A. Non-diagnostic (i.e., low or intermediate probability) ventilation/perfusion lung scan B. Non-diagnostic (i.e., subsegmental defects or technically inadequate study) helical CT scan.
Time frame: Within 90 days post randomization
The diagnosis of proximal DVT requires:
Time frame: Within 90 days post randomization
Pathologic process caused by the invasion of normally sterile tissue or fluid or body cavity by pathogenic or potentially pathogenic organisms.
Time frame: Within 90 days post randomization
Based on the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) criteria,20 sepsis will require a quick Sequential Organ Failure Assessment (qSOFA) Score ≥2 points or patients requiring vasopressors/inotropes due to infection. The qSOFA includes the following items and scoring system:
Time frame: Within 90 days post randomization
Acute infection of the pulmonary parenchyma that is associated with at least one sign or symptom of lower respiratory acute infection (e.g., cough, pleuritic chest pain) or acute systemic illness (e.g., fever, chills, confusion, hypoxemia); accompanied by the presence of an acute infiltrate/consolidation on a chest radiograph or auscultatory findings consistent with pneumonia (such as crackles and/or localized rales) for which there is no other explanation.
Time frame: Within 90 days post randomization
Life threatening, major or critical organ bleeding
Time frame: Within 90 days post randomization
Any second surgical procedure undertaken on the fractured hip being followed in the study, for any reason (e.g. infection, implant failure, periprosthetic fracture, wound dehiscence, etc.), after it has been initially repaired and the patient has left the operating room.
Time frame: Within 90 days post randomization
Any acute dislocation of a prosthetic femoral head from within its intended concentric location within the acetabulum. The acetabulum may or may not be resurfaced/replaced.
Time frame: Within 90 days post randomization
Any mechanical issue related to the integrity of any component of the hip implant which requires a surgical procedure to correct. This includes: loss of implant fixation to bone (either with or without associated periprosthetic fracture); or broken, disassociated, or dislocated implant components.
Time frame: Within 90 days post randomization
Fracture through any part of either the femur and/or acetabulum to which a hip implant used for hip repair/reconstruction was fixed.
Time frame: Within 90 days post randomization
An increase in the serum creatinine concentration from the pre-randomization value of ≥26.5 μmol/L (≥0.3 mg/dL) within 48 hours after randomization, or an increase of ≥50% within 7 days after randomization.
Time frame: Within 90 days post randomization
New requirement for dialysis (i.e., use of hemodialysis machine or peritoneal dialysis apparatus in patients without a requirement for dialysis prior to randomization).
Time frame: Within 90 days post randomization
Hospital re-admission following discharge from index hospitalization
Time frame: Within 90 days post randomization
Length of critical care stay
Time frame: Within 90 days post randomization
Length of rehabilitation stay
Time frame: Within 90 days post randomization
Days alive at home are the number of days patients spend at their usual residence without, during that day, being admitted to a hospital or visiting an emergency department or urgent-care centre. Patients lose days alive at home if 1. patients go to an emergency department or urgent-care centre; 2. they become inpatients at a hospital or rehabilitation or convalescence-care facility; or 3. they die.
Contact information is provided by the study sponsor or research team.
Population Health Research Institute
Other
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 (HIP ATTACK-2) Trial
Acronym: HIP ATTACK-2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07239817
Agnosia, Anesthesia and Analgesia
Milan, Italy
View Trial DetailsNCT06893406
Cervical Myelopathy, Femoral Fractures
Fishers, Indiana, United States
View Trial DetailsNCT07073209
Agnosia, Femoral Fractures
Manhattan, New York, United States
View Trial DetailsNCT04796350
Bone Diseases, Bone Diseases, Metabolic
Innsbruck, Austria
View Trial Details